Using murine models, this study profiles the pathological cell landscape of CRMO by single-cell analysis and suggests that reducing the lifespan of inflammatory myeloid cells by targeting Morrbid can be an effective therapy for chronic osteomyelitis. Here, MIR4435-2HG is linked to chronic recurrent multifocal osteomyelitis.